梅斯健康(02415)附属中标中国中重度斑块状银屑病大型真实世界研究项目

智通财经06-25

智通财经APP讯，梅斯健康(02415)发布公告，近期，公司的子公司上海梅斯医药科技有限公司中标重庆智翔金泰生物制药股份有限公司的“中国中重度斑块状银屑病患者应用塞立奇单抗注射液治疗的疗效和安全性：一项前瞻性、多中心、非干预性大型真实世界研究”的项目，项目金额为约人民币2100万元。集团依托于积累十余年的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446881126?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-25 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446881126","market":"us","top_or_hot":-1,"title":"梅斯健康(02415)附属中标中国中重度斑块状银屑病大型真实世界研究项目","media":"智通财经","content":"<div>\n<p>智通财经APP讯，梅斯健康(02415)发布公告，近期，公司的子公司上海梅斯医药科技有限公司中标重庆智翔金泰生物制药股份有限公司的“中国中重度斑块状银屑病患者应用塞立奇单抗注射液治疗的疗效和安全性：一项前瞻性、多中心、非干预性大型真实世界研究”的项目，项目金额为约人民币2100万元。集团依托于积累十余年的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140297.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>梅斯健康(02415)附属中标中国中重度斑块状银屑病大型真实世界研究项目</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n梅斯健康(02415)附属中标中国中重度斑块状银屑病大型真实世界研究项目\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-25 19:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1140297.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，梅斯健康(02415)发布公告，近期，公司的子公司上海梅斯医药科技有限公司中标重庆智翔金泰生物制药股份有限公司的“中国中重度斑块状银屑病患者应用塞立奇单抗注射液治疗的疗效和安全性：一项前瞻性、多中心、非干预性大型真实世界研究”的项目，项目金额为约人民币2100万元。集团依托于积累十余年的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140297.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1189","symbol_name":"医疗保健技术","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1140297.html","article_id":"2446881126","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446881126","pubTimestamp":1719314889,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，梅斯健康(02415)发布公告，近期，公司的子公司上海梅斯医药科技有限公司中标重庆智翔金泰生物制药股份有限公司的“中国中重度斑块状银屑病患者应用塞立奇单抗注射液治疗的疗效和安全性：一项前瞻性、多中心、非干预性大型真实世界研究”的项目，项目金额为约人民币2100万元。集团依托于积累十余年的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗生态，改善医疗质量。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1189":"医疗保健技术","02415":"梅斯健康"},"translate_title":"Metz Health (02415) won the bid for a large-scale real-world research project on moderate to severe plaque psoriasis in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02415":1},"content_text":"智通财经APP讯，梅斯健康(02415)发布公告，近期，公司的子公司上海梅斯医药科技有限公司中标重庆智翔金泰生物制药股份有限公司的“中国中重度斑块状银屑病患者应用塞立奇单抗注射液治疗的疗效和安全性：一项前瞻性、多中心、非干预性大型真实世界研究”的项目，项目金额为约人民币2100万元。集团依托于积累十余年的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗生态，改善医疗质量。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446881126"}